Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
Public ClinicalTrials.gov record NCT00006385. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Evaluation of Immunization With an HLA-A2 Multi-Epitope Peptide Vaccine Containing MART-1 (NSC #672643), gp100 (NSC #683472), and Tyrosinase (NSC #699048) Peptides Alone or in Combination With GM-CSF, IFN Alpha-2b, or GM-CSF + IFN Alpha-2b in Patients With Metastatic Melanoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Biological therapies such as sargramostim and interferon alfa use different ways to stimulate the immune system and stop cancer cells from growing. It is not yet known if vaccine therapy if more effective with or without biological therapy for melanoma. PURPOSE: Randomized phase II trial to compare the effectiveness of vaccine therapy with or without biological therapy in treating patients who have metastatic melanoma.
Study identification
- NCT ID
- NCT00006385
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- MART-1 antigen Biological
- gp100 antigen Biological
- incomplete Freund's adjuvant Biological
- recombinant interferon alfa Biological
- sargramostim Biological
- tyrosinase peptide Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2000 (Type not available)
- Primary completion
- Oct 2006 (Actual)
- Completion
- Not listed
- Last update posted
- Nov 8, 2011
Started 2000
United States locations
- U.S. sites
- 32
- U.S. states
- 18
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CCOP - Scottsdale Oncology Program | Scottsdale | Arizona | 85259-5404 | — |
| Emory University Hospital - Atlanta | Atlanta | Georgia | 30322 | — |
| Veterans Affairs Medical Center - Atlanta (Decatur) | Decatur | Georgia | 30033 | — |
| Veterans Affairs Medical Center - Lakeside Chicago | Chicago | Illinois | 60611-4494 | — |
| Robert H. Lurie Comprehensive Cancer Center, Northwestern University | Chicago | Illinois | 60611 | — |
| CCOP - Evanston | Evanston | Illinois | 60201 | — |
| CCOP - Carle Cancer Center | Urbana | Illinois | 61801 | — |
| Indiana University Cancer Center | Indianapolis | Indiana | 46202-5289 | — |
| Veterans Affairs Medical Center - Indianapolis (Roudebush) | Indianapolis | Indiana | 46202 | — |
| CCOP - Iowa Oncology Research Association | Des Moines | Iowa | 50309-1016 | — |
| CCOP - Wichita | Wichita | Kansas | 67214-3882 | — |
| CCOP - Ochsner | New Orleans | Louisiana | 70121 | — |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | Maryland | 21231 | — |
| Tuft-New England Medical Center | Boston | Massachusetts | 02111 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| CCOP - Kalamazoo | Kalamazoo | Michigan | 49007-3731 | — |
| CCOP - Northern New Jersey | Hackensack | New Jersey | 07601 | — |
| Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
| Albert Einstein Clinical Cancer Center | The Bronx | New York | 10461 | — |
| Ireland Cancer Center | Cleveland | Ohio | 44106-5065 | — |
| CCOP - Toledo Community Hospital | Toledo | Ohio | 43623-3456 | — |
| CCOP - Geisinger Clinic and Medical Center | Danville | Pennsylvania | 17822-2001 | — |
| University of Pennsylvania Cancer Center | Philadelphia | Pennsylvania | 19104 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| University of Pittsburgh Cancer Institute | Pittsburgh | Pennsylvania | 15213-3489 | — |
| CCOP - Sioux Community Cancer Consortium | Sioux Falls | South Dakota | 57104 | — |
| CCOP - Scott and White Hospital | Temple | Texas | 76508 | — |
| Cancer Center at the University of Virginia | Charlottesville | Virginia | 22908 | — |
| CCOP - St. Vincent Hospital Cancer Center, Green Bay | Green Bay | Wisconsin | 54301 | — |
| Veterans Affairs Medical Center - Madison | Madison | Wisconsin | 53705-2286 | — |
| University of Wisconsin Comprehensive Cancer Center | Madison | Wisconsin | 53792-0001 | — |
| CCOP - Marshfield Medical Research and Education Foundation | Marshfield | Wisconsin | 54449 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00006385, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 8, 2011 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00006385 live on ClinicalTrials.gov.